United-Guardian Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $11.2M-8.0% YoYTTM through 30 Jun 2026
Net Income $2.5M-24.2% YoYTTM through 30 Jun 2026
Free Cash Flow $3.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 49.4% |
| EBITDA Margin | 21.9% |
| Operating Margin | 22.4% |
| Net Margin | 22.0% |
Returns
21.7%ROE
15.6%ROA
21.7%ROIC
Balance Sheet Health
Debt / Equity0.00x
Current Ratio8.05x
Net Debt-$8.1Mnet cash position
Cash & Equivalents$2.4M
Quality Metrics
Altman Z-Score13.70
Piotroski F-Score4 / 9
FCF Margin30.3%
Multi-Year Trend
RevenueFY2025: $10.5M
Diluted EPSFY2025: $0.46
Dividend
$0.25Per share, FY20263.45%Yield-26.0%5-yr growth
Capital Allocation
R&D Spend$480.8K
Capex Intensity0.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Pharmaceuticals | +24.0% | View detailsOptimistic growth driven by expanding domestic sales, improving formulary status with insurance carriers, and broadening outreach to healthcare practitioners. | |
| Cosmetic Ingredients | +21.0% | View detailsPurchasing patterns from ASI have returned to normal levels after inventory destocking in 2025. The company is working to finalize a new distribution agreement with ASI in the first half of 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.